ArticleAmerican journal of public health2010
A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising.
Article in American journal of public health, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Effects of Direct-To-Consumer Advertising on Patient Prescription Requests and Physician Prescribing: A Systematic Review of Psychiatry-Relevant Studies.The Journal of clinical psychiatry · 2016Pooled it
- Critical Test of the Beneficial Consequences of Lifting the Ban on Direct-to-Consumer Advertising for Prescription Drugs in Italy: Experimental Exposure and Questionnaire Study.Journal of medical Internet research · 2023Trial
- The Effect of Including Quantitative Information on Multiple Endpoints in Direct-to-Consumer Prescription Drug Television Advertisements.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Trial
- Taking Repeated Exposure into Account: An Experimental Study of Direct-To-Consumer Prescription Drug Television Ad Effects.Journal of health communication · 2019Trial
- Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements.Research in social & administrative pharmacy : RSAP · 2018Trial
- Illicit use of prescription stimulants in a college student sample: a theory-guided analysis.Drug and alcohol dependence · 2013Trial
- Multi-stakeholder use of patient experience data (PED): current state and future opportunities for the application of PED to inform decision-making.Journal of patient-reported outcomes · 2026Review
- Are we being forthright with the patients about vertebral body tethering? Quality, contemporaneity, and readability analysis of the online content about vertebral body tethering.Spine deformity · 2025Article
- Content Analysis of the Portrayal of Prescription Stimulants on TikTok.Journal of attention disorders · 2025Article
- Presence of Nicotine Warning Statement on US Electronic Nicotine Delivery Systems (ENDS) Advertisements 6 Months Before and After the August 10, 2018 Effective Date.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022Article
- Pharmaceutical Advertising and the Subtle Subversion of Patient Autonomy.The Journal of medical humanities · 2022Article
- Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians.Journal of general internal medicine · 2021Article
- Characterization of US Hospital Advertising and Association With Hospital Performance, 2008-2016.JAMA network open · 2021Article
- Communicative and Discursive Perspectives on the Medication Experience.Pharmacy (Basel, Switzerland) · 2021Article
- Marketing therapy to parents concerned about adolescent substance use: Association of adolescent problems and parent preferences for direct-to-consumer marketing.Professional psychology, research and practice · 2020Article
- Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.Critical reviews in clinical laboratory sciences · 2019Article
- Medicines Information and the Regulation of the Promotion of Pharmaceuticals.Science and engineering ethics · 2019Article
- Communicating Risk Information in Direct-to-Consumer Prescription Drug Television Ads: A Content Analysis.Health communication · 2019Article
- An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs.Annals of family medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in population-level health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.